News

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses ways that changes made to reimbursement models are affecting patient therapies in the biosimilar space.

The partnership will offer an end-to-end manufacturing solution for biopharma companies.

Mark Bouck discusses PharmAlliance’s latest acquisitions, while reiterating its goals surrounding health economics and outcomes research.

The acquisition of the 87,000 square-foot Camden, MD plant provides the CDMO with the ability to offer clinical and commercial non-viral aseptic fill-finish services on four fill lines.

A cross-sectional study explores the broader issue of whether racial segregation in local acute care hospitals exists, while focusing on the demographic of older Black patients enrolled in Medicare.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health, discusses what to expect from Cardinal Health's biosimilars pipeline.

Deal will target neurological diseases, featuring an initial payment of $42 million for Ascidian and up to $1.8 billion in milestone payments/royalties.

The deal also adds a spread of supply chain efficiency, sustainability, and patient safety outcomes to the mix.

In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, explains how digital formats help manufacturers better manage price based on real-time data, along with the impact of NDC-specific price dexterity.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Fran Gregory, PharmD, Vice President of Emerging Therapies, Cardinal Health discusses the growing biosimilars market and the challenges associated with regulation and adoption.

A cross-sectional study among patients with both cancer and a SARS-CoV-2 infection investigates if there were racial and ethnic disparities in treatment delays or discontinuations.

The contract manufacturer financially committed over $107 million into the facility, which can reportedly handle large-scale manufacturing of active ingredients based on messenger ribonucleic acid.

In this Pharmaceutical Commerce video interview, Blake Powers, CEO of Medigi, discusses his first byline with the publication, along with why the industry may be stuck in its ways in certain aspects.

Webinar dives into the trends, technology, and market necessities that can help tackle these obstacles.

The company’s European Hub facility in Roermond is expanding by over 235,000 square feet, and will be dedicated to accommodating freezer farm capacity.

A retrospective cohort study investigates the characteristics of female patients with localized breast cancer that are associated with this nonpersistence.

The 53,000 square-foot facility is expected to become a Northeastern biotech hub, and will be home to various CGT services.

With the standard constantly evolving across the pharma sector, the latest version can help bring benefits to the regulatory process.

The $530 million investment will accelerate the company’s development and production process for therapies in the rare disease space.

A cohort study explores the connection between the rise in Medicare Advantage plan coverage and enrollee satisfaction.

LogiPharma Europe captured many timely topics, including the importance of next-level approaches in aligning temperature-controlled transit and visibility.

The company's latest service provides risk and quality management for the pharma and healthcare sectors.

Causal mediation analysis sought to determine how public hesitancy plays a role in the government procurement of certain vaccines.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Lung-I Cheng, PhD, VP, Head of Cell & Gene Therapy Service Line, Cencora, offers his thoughts on industry pain points and where he envisions the market progressing in terms of its technological capabilities.

Ashfield Event Experiences and WRG merge in an effort to better serve the healthcare industry.

If Congress doesn't act soon, it could result in more health inequities.

An analysis of the general medicine portion of the pharmacy market amid ensuing challenges.

The development and manufacturing plant will be constructed in Texas, and is expected to become operational by Q1 2025.

The courts reversed certain key guidance documents issued by the Health Resources and Services Administration for the 340B Program, which raises uncertainty.

The new plant in Italy is expected to tackle the rise in biopharmaceutical material demand, specifically for GLP-1s.